News | April 30, 2021
Lonza and Moderna enter new agreement to double drug substance production for COVID-19 vaccine
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The company had filed a suit in the High Court of Justice, Ghana
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Subscribe To Our Newsletter & Stay Updated
